newsfilter
← Latest News
GlobeNewswire·

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

ATLANTA, June 16, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease